Boehringer Ingelheim GmbH – Product Pipeline Review – H2 2011

Boehringer Ingelheim GmbH – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Boehringer Ingelheim GmbH - Product Pipeline Review - H2 2011” provides data on the Boehringer Ingelheim GmbH’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Boehringer Ingelheim GmbH’s corporate website, SEC filings, investor presentations and featured press releases, both from Boehringer Ingelheim GmbH and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

• Boehringer Ingelheim GmbH - Brief Boehringer Ingelheim GmbH overview including business description, key information and facts, and its locations and subsidiaries.
• Review of current pipeline of Boehringer Ingelheim GmbH human therapeutic division.
• Overview of pipeline therapeutics across various therapy areas.
• Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
• Product profiles for late stage and clinical stage products of Boehringer Ingelheim GmbH with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
• Recent updates of the Boehringer Ingelheim GmbH’s pipeline in the last quarter.
• Key discontinued and dormant projects.
• Latest news and deals relating to the products.

Reasons to buy

• Evaluate Boehringer Ingelheim GmbH’s strategic position with total access to detailed information on its product pipeline.
• Assess the growth potential of Boehringer Ingelheim GmbH in its therapy areas of focus.
• Identify new drug targets and therapeutic classes in the Boehringer Ingelheim GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
• Exploit collaboration and partnership opportunities with Boehringer Ingelheim GmbH.
• Avoid Intellectual Property Rights related issues.
• Explore the dormant and discontinued projects of Boehringer Ingelheim GmbH and identify potential opportunities in those areas.

Contents

Boehringer Ingelheim GmbH Snapshot
Boehringer Ingelheim GmbH Overview
Key Information
Key Facts
Boehringer Ingelheim GmbH – Research and Development Overview
Key Therapeutic Areas
Boehringer Ingelheim GmbH – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Boehringer Ingelheim GmbH – Pipeline Products Glance
Boehringer Ingelheim GmbH – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Boehringer Ingelheim GmbH Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Boehringer Ingelheim GmbH – Drug Profiles
AbGn-168
  Product Description
  Mechanism of Action
  R&D Progress
BI 201335 + Pegylated Interferon Alpha + Ribavirin
  Product Description
  Mechanism of Action
  R&D Progress
BI 831266
  Product Description
  Mechanism of Action
  R&D Progress
Pramipexole
  Product Description
  Mechanism of Action
  R&D Progress
Volasertib + Afatinib
  Product Description
  Mechanism of Action
  R&D Progress
Boehringer Ingelheim GmbH – Pipeline Analysis
Boehringer Ingelheim GmbH – Pipeline Products by Therapeutic Class
Boehringer Ingelheim GmbH - Pipeline Products By Target
Boehringer Ingelheim GmbH – Pipeline Products by Route of Administration
Boehringer Ingelheim GmbH – Pipeline Products by Molecule Type
Boehringer Ingelheim GmbH – Recent Pipeline Updates
Boehringer Ingelheim GmbH - Dormant Projects
Boehringer Ingelheim GmbH - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
BILN 1941
BIRB 796
Promycin
Boehringer Ingelheim GmbH – Company Statement
Boehringer Ingelheim GmbH – Locations And Subsidiaries
Head Office
Recent Developments
Aug 29, 2011: Boehringer Ingelheim Broadens Breast Cancer Trial Program For Afatinib
Aug 28, 2011: Boehringer Ingelheim's Pradaxa Shows Significant Reduction In Risk Of Stroke Over Warfarin In Patients With Atrial Fibrillation Taking Antiplatelet Or Other Concomitant Therapies
Jun 28, 2011: Zealand Pharma Presents New Preclinical Data On ZP2929 In Disease Models For Diabetes And Obesity At American Diabetes Association's 71st Annual Scientific Sessions
Oct 27, 2011: Boehringer Ingelheim Implements Additional Guidance Supporting Appropriate Use Of Pradaxa In Europe
Sep 27, 2011: BIBF 1120 In Patients With Metastatic Colorectal Cancer As Effective As Bevacizumab With Less Serious Adverse Events
Jul 27, 2011: Viramune (nevirapine) Prolonged-Release Once-Daily Formulation For The Treatment Of HIV-1 Infection Receives CHMP Recommendation For Approval
Jun 27, 2011: Ablynx Receives €5m In Milestone Payment From Alzheimer's Disease Collaboration With Boehringer Ingelheim
Jun 27, 2011: New Data For Linagliptin Show Clinically Meaningful Efficacy Similar To Glimepiride But With Fewer Cardiovascular Events
Aug 26, 2011: Boehringer Ingelheim To Launch RE-ALIGN Trial To Evaluate Dabigatran Etexilate In Patients With Mechanical Heart Valves
Aug 26, 2011: Boehringer Ingelheim's Pradaxa Revolutionizes Stroke Prevention In Atrial Fibrillation
Apr 26, 2011: Boehringer Ingelheim Initiates Enrollment In Phase III Trial For Lead Hepatitis C Compound
May 25, 2011: Boehringer Ingelheim To Present New Data On Afatinib At ASCO 2011 Annual Meeting
Mar 24, 2011: The POET-COPD Study Results Demonstrate Superiority Of Spiriva Over Long-acting Beta Agonist Salmeterol In Reducing Risk For COPD Exacerbations
Oct 21, 2011: Boehringer Ingelheim To Present SILEN-C1 And SILEN-C3 Clinical Data At 62nd Annual Meeting Of The American Association For The Study Of Liver Diseases
Oct 21, 2011: Boehringer Ingelheim To Present SOUND-C2 Clinical Study Data At 62nd Annual Meeting Of The American Association For The Study Of Liver Diseases
Sep 21, 2011: Boehringer Ingelheim Enrolls First Patient In Phase III Program For New Once-Daily Fixed-Dose Combination Of Tiotropium Plus Olodaterol In COPD
Jan 21, 2011: Boehringer Ingelheim’s PRAZAXA Wins Approval In Japan For Stroke Prevention In Atrial Fibrillation
Aug 16, 2011: NICE Asks For More Information Of Boehringer's Pradaxa For People With Common Heart Condition
Oct 07, 2011: FDA Approves Combivent Respimat Inhalation Spray For Treatment Of Patients With Chronic Obstructive Pulmonary Disease
Oct 07, 2009: Astellas and Boehringer Ingelheim Reach Settlement with Impax on FLOMAX Patent Case
Sep 07, 2011: Boehringer Ingelheim And Lilly To Present Latest Data From Empagliflozin At 47th Annual Meeting Of European Association For Study Of Diabetes
Sep 06, 2011: Boehringer Ingelheim Broadens Breast Cancer Phase II Clinical Trial Program For Afatinib
Jan 05, 2011: New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion
Aug 04, 2011: Boehringer Receives European Commission Approval For Pradaxa For Stroke Prevention In Patients With Atrial Fibrillation
Jul 04, 2011: Ark Therapeutics Receives Notice Of Allowance For Two US Patents
Apr 01, 2011: Boehringer Ingelheim Announces Sustained Viral Response Achieved In 83% Of Hepatitis C Infected Patients With New HCV Protease Inhibitor
Financial Deals Landscape
Boehringer Ingelheim GmbH, Deals Summary
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Boehringer Ingelheim Acquires Fremont Facility From Amgen
Boehringer Ingelheim Acquires Protein Material And Specific Functional Assay From Axxam
Boehringer Ingelheim Acquires Zantac From Pfizer
Partnerships
Orexo Extends Licensing Agreement With Boehringer
Ablynx Enters Into Licensing Agreement With Boehringer Ingelheim
Vectura Signs An Agreement With Boehringer Ingelheim
Nuevolution Enters Into Co-Development Agreement With Boehringer Ingelheim
Pfenex Enters Into Collaboration With Boehringer Ingelheim
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim
Eli Lilly Enters Into Co-Development Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Co-Marketing Agreement With VTU Technology
Boehringer Ingelheim Enters Into Co-Development Agreement With MacroGenics
Boehringer Ingelheim Enters Into Collaboration Agreement With Micromet
Boehringer Ingelheim Enters Into Co-Development Agreement With Priaxon
Evotec Extends Research Collaboration With Boehringer Ingelheim
Boehringer Ingelheim Partners With Vitae Pharmaceuticals
Kemwell Enters Into Strategic Collaboration Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Collaboration With DeveloGen
Exelixis Enters Into Co-Development Agreement With Boehringer Ingelheim
Antitope Enters Into Research Agreement With Boehringer Ingelheim
Ablynx Extends Agreement With Boehringer Ingelheim
Proximagen Neuroscience Enters Into Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into An Agreement With Vitae Pharmaceuticals
NascaCell Enters Into Co-Development Agreement With Boehringer Ingelheim
Ablynx Enters Into Co-Development Agreement With Boehriner Ingelheim
Boehringer Ingelheim Enters Into Licensing Agreement With Biolipox
Boehringer Ingelheim Signs An Agreement With AbGenomics
Artemis Pharmaceuticals Enters Into Licensing Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into An Licensing Agreement With Eidogen
Equity Offering
Ablynx Completes Initial Public Offering Of $121.19 Million
Vectura Group Completes Private Placement Of $7.22 Million
Vectura Group Completes Private Placement Of $12.83 Million
Debt Offering
Boehringer Ingelheim Completes Private Placement Of Bonds For $1,250.5 Million
Asset Transactions
Eli Lilly Reacquires Rights To Yentreve From Boehringer Ingelheim
Acquisition
Boehringer Ingelheim Acquires An Additional 33.6% Stake In SSP
Boehringer Ingelheim Acquires Actimis Pharmaceuticals
Boehringer Ingelheim Acquires STEAG microParts From STEAG
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Boehringer Ingelheim GmbH – Pipeline by Therapy Area and Indication, H2 2011
Boehringer Ingelheim GmbH – Pipeline by Stage of Development, H2 2011
Boehringer Ingelheim GmbH – Monotherapy Products in Pipeline, H2 2011
Boehringer Ingelheim GmbH – Combination Treatment Modalities in Pipeline, H2 2011
Boehringer Ingelheim GmbH – Phase III, H2 2011
Boehringer Ingelheim GmbH - Phase I, H2 2011
Boehringer Ingelheim GmbH - Pipeline By Therapeutic Class, H2 2011
Boehringer Ingelheim GmbH - Pipeline By Target, H2 2011
Boehringer Ingelheim GmbH – Pipeline By Route of Administration, H2 2011
Boehringer Ingelheim GmbH – Pipeline By Molecule Type, H2 2011
Boehringer Ingelheim GmbH – Recent Pipeline Updates, H2 2011
Boehringer Ingelheim GmbH - Dormant Developmental Projects, 2010
Boehringer Ingelheim GmbH - Discontinued Pipeline Products, 2010
Boehringer Ingelheim GmbH, Deals Summary
Boehringer Ingelheim Acquires Fremont Facility From Amgen
Boehringer Ingelheim Acquires Protein Material And Specific Functional Assay From Axxam
Boehringer Ingelheim Acquires Zantac From Pfizer
Orexo Extends Licensing Agreement With Boehringer
Ablynx Enters Into Licensing Agreement With Boehringer Ingelheim
Vectura Signs An Agreement With Boehringer Ingelheim
Nuevolution Enters Into Co-Development Agreement With Boehringer Ingelheim
Pfenex Enters Into Collaboration With Boehringer Ingelheim
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim
Eli Lilly Enters Into Co-Development Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Co-Marketing Agreement With VTU Technology
Boehringer Ingelheim Enters Into Co-Development Agreement With MacroGenics
Boehringer Ingelheim Enters Into Collaboration Agreement With Micromet
Boehringer Ingelheim Enters Into Co-Development Agreement With Priaxon
Evotec Extends Research Collaboration With Boehringer Ingelheim
Boehringer Ingelheim Partners With Vitae Pharmaceuticals
Kemwell Enters Into Strategic Collaboration Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Collaboration With DeveloGen
Exelixis Enters Into Co-Development Agreement With Boehringer Ingelheim
Antitope Enters Into Research Agreement With Boehringer Ingelheim
Ablynx Extends Agreement With Boehringer Ingelheim
Proximagen Neuroscience Enters Into Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into An Agreement With Vitae Pharmaceuticals
NascaCell Enters Into Co-Development Agreement With Boehringer Ingelheim
Ablynx Enters Into Co-Development Agreement With Boehriner Ingelheim
Boehringer Ingelheim Enters Into An Agreement With Proteros biostructures
Evotec Enters Into Co-Development Agreement With Boehringer Ingelheim
Axxam Enters Into Drug Discovery Collaboration With Boehringer Ingelheim
Graffinity Pharmaceuticals Expands Its Research Agreement With Boehringer Ingelheim Pharmaceuticals
Biota Holdings Enters Into An Agreement With Boehringer Ingelheim
FivePrime Therapeutics Enters Into Research Agreement With Boehringer Ingelheim
Evotec And Evotec Neurosciences Amends Co-Development Agreement With Boehringer Ingelheim
Astex Therapeutics Enters Into Co-Development Agreement With Boehringer Ingelheim
Caprion Pharmaceuticals Enters Into Research Collaboration With Boehringer Ingelheim
Biotest AG Enters Into Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Agreement With Medarex
Depomed Enters Into Agreement With Boehringer Ingelheim
Boehringer Ingelheim Expands Research Agreement With MorphoSys
Avidia Research Institute Enter Into Agreement With Boehringer Ingelheim Austria
Evotec And Evotec Neurosciences Enter Into Research Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into An Agreement With MorphoSys
Boehringer Ingelheim Enters Into An Co-Promotion Agreement For FLOMAX With Yamanouchi
Astex Technology Enters Into Drug Discovery Agreement With Boehringer Ingelheim
Zydus Cadila Healthcare Enters Into An Agreement With Boehringer Ingelheim India
Boehringer Ingelheim Enters Into Co-Development Agreement With Morphochem
Ingenuity Systems Enters Into Licensing Agreement With Boehringer Ingelheim
Ark Therapeutics Signs Licencing Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436
Boehringer Ingelheim Enters Into Licensing Agreement With ProBioGen
Zealand Pharma Enters Into Licensing And Collaboration Agreement With Boehringer Ingelheim
Depomed Enters Into Licensing Agreement With Boehringer Ingelheim
f-star Biotechnologische Enters Into Licensing Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Licensing Agreement With Fresenius Kabi Deutschland
Marinomed Biotechnologie Enters Into Licensing Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Licensing Agreement With Evec
Boehringer Ingelheim Enters Into Licensing Agreement With BioFocus DPI
Euroscreen Enters Into Licensing Agreement With Boehringer Ingelheim
GeneGo Expands Licensing Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Licensing Agreement With Xencor
Boehringer Ingelheim Enters Into Licensing Agreement With MorphoSys
GeneGo Enters Into Licensing Agreement With Boehringer Ingelheim
XstalBio Signs Licensing Agreement With Boehringer Ingelheim
Ingenuity Systems Enters Into Licensing Agreement With Boehringer Ingelheim For IPA
Inspire Pharmaceuticals Enters Into Licensing Agreement With Boehringer Ingelheim
TransTech Pharma Enters Into Research And Licensing Agreement With Boehringer Ingelheim
Orexo Enters Into Licensing Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Licensing Agreement With Biolipox
Boehringer Ingelheim Signs An Agreement With AbGenomics
Artemis Pharmaceuticals Enters Into Licensing Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into An Licensing Agreement With Eidogen
Ablynx Completes Initial Public Offering Of $121.19 Million
Vectura Group Completes Private Placement Of $7.22 Million
Vectura Group Completes Private Placement Of $12.83 Million
Boehringer Ingelheim Completes Private Placement Of Bonds For $1,250.5 Million
Eli Lilly Reacquires Rights To Yentreve From Boehringer Ingelheim
Boehringer Ingelheim Acquires An Additional 33.6% Stake In SSP
Boehringer Ingelheim Acquires Actimis Pharmaceuticals
Boehringer Ingelheim Acquires STEAG microParts From STEAG

LIST OF FIGURES

Boehringer Ingelheim GmbH – Pipeline by Therapy Area and Indication, H2 2011
Boehringer Ingelheim GmbH – Pipeline by Stage of Development, H2 2011
Boehringer Ingelheim GmbH – Monotherapy Products in Pipeline, H2 2011
Boehringer Ingelheim GmbH – Combination Treatment Modalities in Pipeline, H2 2011
Boehringer Ingelheim GmbH – Pipeline By Therapeutic Class, H2 2011
Boehringer Ingelheim GmbH - Pipeline By Target, H2 2011
Boehringer Ingelheim GmbH – Pipeline By Route of Administration, H2 2011
Boehringer Ingelheim GmbH – Pipeline By Molecule Type, H2 2011 Skip to top